Featuring an interview with Dr Sagar Lonial, including the following topics:

• Phase 3 randomized study evaluating teclistamab and daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib for patients with relapsed/refractory (R/R) multiple myeloma (MM) (0:00)
• Management of belantamab mafodotin-associated ocular events with dose modifications guided by standard assessments (3:15)
• Belantamab mafodotin in combination with bortezomib, lenalidomide and dexamethasone for transplant-ineligible patients with newly diagnosed MM (8:00)
• Other investigational strategies for R/R MM (12:55)

CME information and select publications

Featuring an interview with Dr Marwan Fakih, including the following topics:

• Etiology and incidence of squamous cell carcinoma of the anal canal (SCAC) (0:00)
• Novel therapeutic strategies for the treatment of SCAC: Immunotherapy combinations and monitoring for recurrence with circulating tumor DNA assessment (4:37)
• Perspectives on the overall survival benefit observed with first-line retifanlimab and carboplatin/paclitaxel; potential for cure for patients with SCAC (8:22)
• Case: A woman in her mid 60s with recurrent unresectable metastatic SCAC receives retifanlimab with carboplatin/paclitaxel (16:56)
• Case: A woman in her mid 60s with recurrent unresectable metastatic SCAC receives single-agent immunotherapy (25:22)
• Case: A woman in her 60s with previously untreated metastatic SCAC receives chemotherapy and attains a complete response (29:21)
• Future directions for the treatment of SCAC (33:22)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Marwan Fakih, including the following topics:

• Overview of etiology, incidence and staging of squamous cell cancer of the anal canal (SCAC) (0:00)
• Systemic therapy approaches to the management of recurrent unresectable and metastatic SCAC (6:17)
• Available data with anti-PD-1 (pembrolizumab, nivolumab, retifanlimab) and anti-CTLA-4 (ipilimumab) agents in the management of unresectable metastatic SCAC previously treated with chemotherapy (12:59)
• Immunotherapy combined with chemotherapy for the front-line treatment of SCAC (20:48)
• Efficacy and safety of retifanlimab combined with carboplatin/paclitaxel as first-line treatment for SCAC in the Phase III POD1UM-303 trial (23:43)

CME information and select publications

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics:

• EMBARK trial: Enzalutamide for biochemically recurrent prostate cancer (0:00)
• Final results from the Phase III PRESTO study: Combined androgen blockade for high-risk biochemically relapsed prostate cancer (4:05)
• Other novel treatment strategies for patients with metastatic prostate cancer (10:31)

CME information and select publications

Featuring an interview with Dr Kathleen N Moore, including the following topics:

• Overview of the mechanism of action and pharmacology of antibody-drug conjugates (ADCs) (0:00)
• Comparing toxicities of conventional chemotherapy and ADCs (6:26)
• Potential of ADCs as maintenance therapy for ovarian cancer (11:35)
• Treatment based on platinum sensitivity and homologous recombination-deficiency status (15:10)
• Case: A woman in her mid 70s presenting with Stage IV ovarian cancer receives raludotatug deruxtecan (18:46)
• Case: A woman in her mid 60s with relapsed/refractory ovarian cancer receives mirvetuximab soravtansine (41:22)
• Case: A woman in her early 70s with relapsed/refractory ovarian cancer receives multiple ADCs in clinical trials (45:57)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Kathleen N Moore, including the following topics:

• Overview of developments and opportunities with antibody-drug conjugates (ADCs) in ovarian cancer(0:00)
• Targeting folate receptor alpha with mirvetuximab soravtansine (3:59)
• Targeting TROP2 with ADCs (9:12)
• Targeting folate receptor alpha with ADCs (14:17)
• Targeting cadherin-6 with ADCs (17:27)
• Targeting HER2 with ADCs (26:12)
• Potential of ADCs in the treatment of platinum-sensitive ovarian cancer (28:38)

CME information and select publications

Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics:

• Introduction (0:00)
• Neoadjuvant Treatment for Localized Colorectal Cancer (CRC) — Dr Seligmann (2:39)
• Emerging Novel Approaches to Adjuvant Treatment for Localized CRC — Dr Lieu (33:18)
• Role of Circulating Tumor DNA Testing in Localized CRC — Dr Cohen (59:43)

CME information and select publications

Featuring perspectives from Dr Hanny Al-Samkari, Dr Cindy Neunert and Prof Francesco Zaja, including the following topics:

• Introduction (0:00)
• Case: A woman in her early 30s with chronic relapsing immune thrombocytopenia (ITP) receives eltrombopag with ongoing stabilization of platelet counts — Neil Morganstein, MD (2:03)
• Case: A woman in her late 60s with a long history of ITP controlled by eltrombopag experiences acute exacerbations — Bhavana (Tina) Bhatnagar, DO (6:42)
• Clinical Manifestations and Initial Management of ITP — Dr Neunert (18:07)
• Case: A woman in her early 80s with metastatic adenocarcinoma of the lung who responded to carboplatin/pemetrexed/pembrolizumab presents with ITP after 14 months of maintenance pembrolizumab — Susmitha Apuri, MD (33:14)
• Incorporation of Thrombopoietin Receptor Agonists and Other Second-Line Therapies into ITP Management — Prof Zaja (40:19)
• Case: A woman in her late 60s with stress cardiomyopathy and corticosteroid-refractory ITP receives rituximab followed by eltrombopag — Eric Fox, DO (1:00:44)
• Current and Future Role of Novel Therapies in ITP — Dr Al-Samkari (1:03:47)

CME information and select publications